Skip to main content
Premium Trial:

Request an Annual Quote

Verisante Inks Deal for $2.8M in Funding and Chinese Distribution

Premium

NEW YORK (GenomeWeb) – Verisante said this week that it has closed a non-brokered private placement of 2 million common shares at a price of $.15 per share, raising a total of $300,000.

The placement comes in conjunction with the company's agreement with an unnamed strategic partner for exclusive marketing and sales rights to its Raman spectroscopy-based Core cancer detection system and ClearVu endoscopic camera.

This agreement is contingent on Verisante receiving an additional $2.5 million in investment by the end of September 2014. That private placement will be for common shares discounted below the market price at a rate of no greater than 15 percent.

Under the agreement, the unnamed partner will fund the China Food & Drug Administration approval process for products beginning with the Core for lung cancer, including additional clinical trials if needed.

The Scan

Myotonic Dystrophy Repeat Detected in Family Genome Sequencing Analysis

While sequencing individuals from a multi-generation family, researchers identified a myotonic dystrophy type 2-related short tandem repeat in the European Journal of Human Genetics.

TB Resistance Insights Gleaned From Genome Sequence, Antimicrobial Response Assays

Researchers in PLOS Biology explore M. tuberculosis resistance with a combination of sequencing and assays looking at the minimum inhibitory concentrations of 13 drugs.

Mendelian Disease Genes Prioritized Using Tissue-Specific Expression Clues

Mendelian gene candidates could be flagged for further functional analyses based on tissue-specific transcriptome and proteome profiles, a new Journal of Human Genetics paper says.

Single-Cell Sequencing Points to Embryo Mosaicism

Mosaicism may affect preimplantation genetic tests for aneuploidy, a single-cell sequencing-based analysis of almost three dozen embryos in PLOS Genetics finds.